A fast exit from discovery-phase development is the most prominent change in a pharmaceutical industry coping with economic contraction, according to speakers at the Licensing Executives Society annual meeting. David Flores, president of BioCentury, moderated the Oct. 17 session and detailed a barren market landscape for new drug development rooted in shrinking venture capital, higher regulatory hurdles, and a ‘‘duplication of futility, with competitors going after the same targets and pathways.’’

Seminar Information
Seminar Date:
November 22, 2011
Pharma Companies Increasingly Leaving Early-Stage Research to Others, Panel Says
Individual topic purchase: Selected
Online Materials
LES Member Price:$0.00
Non-Member Price:$0.00